Exosect to adopt licensing business model

Exosect recently announced the completion of the company’s transition from direct product sales to a licensing model.  Over the past two years the company has expanded the scope of its research and development to improve delivery of formulations for a wider range of active ingredients, synthetic and biological, opening up its technology to collaboration in the pesticide industry.

To communicate these changes a new web site (www.exosect.com) has been launched providing a clear overview of the technology platforms with the development and business opportunities.

The venture capital funded technology company partners with pesticide manufacturers, using its proprietary micro powder platforms to improve the efficiency of their formulations, to overcome issues such as pest resistance, regulatory control and residues within the food chain.
 
The company is focused on two main technology platforms - Entostat, a wax based micro-powder and Entomag, a lipid coated ferrous micro-powder, both exhibit inherent adhesive properties. Entostat readily gains an electrostatic charge and adheres to a range of surfaces including grains seeds, insects, animals and building fabrics. Both platforms enable the targeted delivery of biological and synthetic active ingredients with reduced environmental impact.

CEO, Martin Brown, joined the company in 2004. “We have developed a significant amount of knowhow and an extensive intellectual property portfolio. Two years ago we began the process of re-aligning the business. During the transition period we have been consolidating our existing products business whilst growing our portfolio of licensing partners. We are now in a position to focus entirely on our partnerships and are launching our new website to fully reflect what we do”. Brown continues, “We are focussing the technology on the Agricultural, Public Health and Animal Health sectors.  There are future opportunities within the retail and consumer markets. “